Toxic and Metabolic Disease



White Matter Cytotoxic Edema Central Pontine Myelinolysis Canavan Disease Diffuse White Matter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lexa FJ (1995) Drug-induced disorders of the central nervous system. Seminars in Roentgenol 30:7–17Google Scholar
  2. 2.
    Brown MS, Stemmer SM, Simon JH, et al. (1998) White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol 19:217–221PubMedGoogle Scholar
  3. 3.
    Fujikawa A, Tsuchiya K, Katase S, Kurosaki Y, Hachiya J (2001) Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. Eur Radiol 11:2602–2606CrossRefPubMedGoogle Scholar
  4. 4.
    Tha KK, Terae S, Sugiura M, et al. (2002) Diffusion-weighted magnetic resonance imaging in early stage of 5-fluorouracil-induced leukoencephalopathy. Acta Neurol Scand 106:379–386CrossRefPubMedGoogle Scholar
  5. 5.
    Matsumoto S, Nishizawa S, Murakami S, et al. (1995) Carmofur-induced leukoencephalopathy: MRI. Neuroradiology 37:649–652CrossRefPubMedGoogle Scholar
  6. 6.
    Maschke M, Fehlings T, Kastrup O, Wilhelm HW, Leonhardt G (1999) Toxic leukoencephalopathy after intravenous consumption of heroin and cocaine with unexpected clinical recovery. J Neurol 246:850–851CrossRefPubMedGoogle Scholar
  7. 7.
    Wolters EC, van Wijngaarden GK, Stam FC, et al (1982) Leucoencephalopathy after inhaling “heroin” pyrolysate. Lancet 2:1233–1237CrossRefPubMedGoogle Scholar
  8. 8.
    Tan TP, Algra PR, Valk J, Wolters EC (1994) Toxic leukoencephalopathy after inhalation of poisoned heroin: MR findings. Am J Neuroradiol 15:175–178PubMedGoogle Scholar
  9. 9.
    Chen CY, Lee KW, Lee CC, Chin SC, Chung HW, Zimmerman RA (2000) Heroin-induced spongiform leukoencephalopathy: value of diffusion MR imaging. J Comput Assist Tomogr 24:735–737CrossRefPubMedGoogle Scholar
  10. 10.
    Barnett MH, Miller LA, Reddel SW, Davies L (2001) Reversible delayed leukoencephalopathy following intravenous heroin overdose. J Clin Neurosci 8:165–167CrossRefPubMedGoogle Scholar
  11. 11.
    Gocht A, Colmant HJ (1987) Central pontine and extrapontine myelinolysis: a report of 58 cases. Clin Neuropathol 6:262–270PubMedGoogle Scholar
  12. 12.
    Sterns RH, Riggs JE, Schochet SS Jr (1986) Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 314:1535–1542PubMedGoogle Scholar
  13. 13.
    Ho VB, Fitz CR, Yoder CC, Geyer CA (1993) Resolving MR features in osmotic myelinolysis (central pontine and extrapontine myelinolysis. Am J Neuroradiol 14:163–167PubMedGoogle Scholar
  14. 14.
    Norenberg MD (1983) A hypothesis of osmotic endothelial injury. A pathogenetic mechanism in central pontine myelinolysis. Arch Neurol 40:66–69PubMedGoogle Scholar
  15. 15.
    Mascalchi M, Cincotta M, Piazzini M (1993) Case report: MRI demonstration of pontine and thalamic myelinolysis in a normonatremic alcoholic. Clin Radiol 47:137–138PubMedGoogle Scholar
  16. 16.
    Rodriguez J, Benito-Leon J, Molina JA, Ramos A, Bermejo F (1998) Central pontine myelinolysis associated with cyclosporin in liver transplantation. Neurologia 13:437–440PubMedGoogle Scholar
  17. 17.
    Miller RF, Harrison MJ, Hall-Craggs MA, Scaravilli F (1998) Central pontine myelinolysis in AIDS. Acta Neuropathol 96:537–540PubMedGoogle Scholar
  18. 18.
    Cramer SC, Stegbauer KC, Schneider A, Mukai J, Maravilla KR (2001) Decreased diffusion in central pontine myelinolysis. AJNR Am J Neuroradiol 22:1476–1479PubMedGoogle Scholar
  19. 19.
    Anderson AW, Zhong J, Petroff OA, et al (1996) Effects of osmotically driven cell volume changes on diffusion-weighted imaging of the rat optic nerve. Magn Reson Med 35:162–167PubMedGoogle Scholar
  20. 20.
    Victor M,Adams RD, Collins GH (1971) The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. Contemp Neurol Ser 7:1–206PubMedGoogle Scholar
  21. 21.
    Antunez E, Estruch R, Cardenal C, Nicolas JM, Fernandez-Sola J, Urbano-Marquez A (1998) Usefulness of CT and MR imaging in the diagnosis of acute Wernicke’s encephalopathy. AJR Am J Roentgenol 171:1131–1137PubMedGoogle Scholar
  22. 22.
    Oka M, Terae S, Kobayashi R, et al. (2001) Diffusion-weighted MR findings in a reversible case of acute Wernicke encephalopathy. Acta Neurol Scand 104:178–181CrossRefPubMedGoogle Scholar
  23. 23.
    Doherty MJ, Watson NF, Uchino K, Hallam DK, Cramer SC (2002) Diffusion abnormalities in patients with Wernicke encephalopathy. Neurology 58:655–657PubMedGoogle Scholar
  24. 24.
    Chu K, Kang DW, Kim HJ, Lee YS, Park SH (2002) Diffusion-weighted imaging abnormalities in wernicke encephalopathy: reversible cytotoxic edema? Arch Neurol 59:123–127CrossRefPubMedGoogle Scholar
  25. 25.
    Rugilo CA, Roca MC, Zurru MC, Gatto EM (2003) Diffusion abnormalities and Wernicke encephalopathy. Neurology 60:727–728; author reply 727–728Google Scholar
  26. 26.
    Gambini A, Falini A, Moiola L, Comi G, Scotti G (2003) Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study. Am J Neuroradiol 24:249–253PubMedGoogle Scholar
  27. 27.
    Gass A, Birtsch G, Olster M, Schwartz A, Hennerici MG (1998) Marchiafava-Bignami disease: reversibility of neuroimaging abnormality. J Comput Assist Tomogr 22:503–504CrossRefPubMedGoogle Scholar
  28. 28.
    Inagaki T, Saito K (2000) A case of Marchiafava-Bignami disease demonstrated by MR diffusion-weighted image. No To Shinkei 52:633–637PubMedGoogle Scholar
  29. 29.
    Oppenheim C, Galanaud D, Samson Y, et al. (2000) Can diffusion weighted magnetic resonance imaging help differentiate stroke from stroke-like events in MELAS? J Neurol Neurosurg Psychiatry 69:248–250CrossRefPubMedGoogle Scholar
  30. 30.
    Yoneda M, Maeda M, Kimura H, Fujii A, Katayama K, Kuriyama M (1999) Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology 53: 2182–2184PubMedGoogle Scholar
  31. 31.
    Yonemura K, Hasegawa Y, Kimura K, Minematsu K, Yamaguchi T (2001) Diffusion-weighted MR imaging in a case of mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. AJNR Am J Neuroradiol 22:269–272PubMedGoogle Scholar
  32. 32.
    Ohshita T, Oka M, Imon Y, et al. (2000) Serial diffusion-weighted imaging in MELAS. Neuroradiology 42:651–656CrossRefPubMedGoogle Scholar
  33. 33.
    Kim HS, Kim DI, Lee BI, et al. (2001) Diffusion-weighted image and MR spectroscopic analysis of a case of MELAS with repeated attacks. Yonsei Med J 42:128–133PubMedGoogle Scholar
  34. 34.
    Majoie CB, Akkerman EM, Blank C, Barth PG, Poll-The BT, den Heeten GJ (2002) Mitochondrial encephalomyopathy: comparison of conventional MR imaging with diffusion-weighted and diffusion tensor imaging: case report. AJNR Am J Neuroradiol 23:813–816PubMedGoogle Scholar
  35. 35.
    Flemming K, Ulmer S, Duisberg B, Hahn A, Jansen O (2002) MR spectroscopic findings in a case of Alpers-Huttenlocher syndrome. AJNR Am J Neuroradiol 23:1421–1423PubMedGoogle Scholar
  36. 36.
    Huttenlocher PR (2000) The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr Suppl 2:S102–S106Google Scholar
  37. 37.
    Pearsen KD, Gean-Marton AD, Levy HL, Davis KR (1990) Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology 177:437–440PubMedGoogle Scholar
  38. 38.
    Phillips MD, McGraw P, Lowe MJ, Mathews VP, Hainline BE (2001) Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria. AJNR Am J Neuroradiol 22:1583–1586PubMedGoogle Scholar
  39. 39.
    Ono J, Harada K, Mano T, Sakurai K, Okada S (1997) Differentiation of dysand demyelination using diffusional anisotropy. Pediatr Neurol 16:63–66CrossRefPubMedGoogle Scholar
  40. 40.
    Engelbrecht V, Scherer A, Rassek M, Witsack HJ, Modder U (2002) Diffusion-weighted MR imaging in the brain in children: findings in the normal brain and in the brain with white matter diseases. Radiology 222:410–418PubMedGoogle Scholar
  41. 41.
    Sener RN (2003) Canavan disease: diffusion magnetic resonance imaging findings. J Comput Assist Tomogr 27:30–33PubMedGoogle Scholar
  42. 42.
    Eichler FS, Itoh R, Barker PB, et al. (2002) Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience. Radiology 225:245–252PubMedGoogle Scholar
  43. 43.
    Sener RN (2002) Metachromatic leukodystrophy: diffusion MR imaging findings. AJNR Am J Neuroradiol 23:1424–1426PubMedGoogle Scholar
  44. 44.
    Sener RN (2003) L-2 hydroxyglutaric aciduria: proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging findings. J Comput Assis Tomo 27:38–43CrossRefGoogle Scholar
  45. 45.
    Sener RN (2003) Diffusion magnetic resonance imaging in infantile neuroaxonal dystrophy. J Comput Assis Tomo 27:34–37CrossRefGoogle Scholar
  46. 46.
    Ellison D, Love S (1998) Toxic injury of the CNS. In: Neuropathology, 1st edn, section 8, chapter 25. Barcelona, Mosby, pp 25.1–25.22Google Scholar
  47. 47.
    Ono J, Harada K, Sakurai K, et al. (1994) MR diffusion imaging in Pelizaeus-Merzbacher disease. Brain Dev 16:219–223CrossRefPubMedGoogle Scholar
  48. 48.
    Guo AC, Petrella JR, Kurtzberg J, Provenzale JM (2001) Evaluation of white matter anisotropy in Krabbe disease with diffusion tensor MR imaging: initial experience. Radiology 218:809–815PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations